Evidence map›Paper›PMID 26550371›Full record

ArticleInternational journal of clinical and experimental medicine2015

Distribution of monocyte chemoattractant protein-1 (MCP-1 A-2518G) and chemokine receptor (CCR2-V64Ι) gene variants in hyperbilirubinemic newborns.

Fatma Narter, Elif Sinem Bireller, Can Engin, Tolga Catmakas, Fehmi Narter, Arzu Ergen, Bedia Cakmakoglu

Abstract read
In one paragraph

Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Fatma NarterDepartment of Pediatrics, Division of Neonatology, Kartal Dr. Lutfi Kırdar Education and Training Hospital Kartal, Istanbul, Turkey.
Elif Sinem BirellerDepartment of Molecular Medicine, Istanbul University, Institute of Experimental Medical Research Capa, Istanbul, Turkey.
Can EnginDepartment of Molecular Medicine, Istanbul University, Institute of Experimental Medical Research Capa, Istanbul, Turkey.
Tolga CatmakasDepartment of Molecular Medicine, Istanbul University, Institute of Experimental Medical Research Capa, Istanbul, Turkey.
Fehmi NarterDepartment of Urology, Kartal Dr. Lutfi Kırdar Education and Training Hospital Kartal, Istanbul, Turkey.
Arzu ErgenDepartment of Molecular Medicine, Istanbul University, Institute of Experimental Medical Research Capa, Istanbul, Turkey.
Bedia CakmakogluDepartment of Molecular Medicine, Istanbul University, Institute of Experimental Medical Research Capa, Istanbul, Turkey.
Istanbul University · TRDr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperbilirubinemia is one of the most crucial syndromes, which is characterized by high levels of bilirubin, especially when it occurs in newborns. Bilirubin has cytoprotective properties with an antioxidant function and plays several major roles in the inflammation process with its members such as chemokines. The monocyte chemoattractant protein-1 (MCP-1) is a member of the C-C chemokine family and it has been associated with the inflammatory process. There are no data on the chemokine and its receptor genotypes in hyperbilirubinemic newborns to show their distribution. The aim of this study is to investigate the genotypic relationship of MCP-1 and its receptor CCR2-V64Ι with hyperbilirubinemia in Turkish newborns. A total of 85 newborns were included in the study: 20 infants with hyperbilirubinemia (hyperbilirubinemic group) and 65 infants without hyperbilirubinemia (non-hyperbilirubinemic group). Genotyping of MCP-1 A-2518G and CCR2-V64Ι gene polymorphisms were detected by PCR-RFLP, respectively. MCP-1 GG genotype in patients was higher than the controls and this genotype had 2.69 times higher risk for hyperbilirubinemic neonates (P: 0.20). The frequency of MCP-1 A-2518G G+ genotype in patients was higher than the controls (55.0% and 38.5%, respectively). The results of our preliminary study suggest that MCP-1 G+ genotype has the ability to increase the hyperbilirubinemia risk of newborns. These results should be focused on to research on a larger scale to confirm the findings.

Indexed as

CCR2hyperbilirubinemiaMCP-1 and newborn

Identifiers

PMID26550371
PMCPMC4613056
OpenAlexW2191513328

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.